AU2011234656B2 - Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant - Google Patents

Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant Download PDF

Info

Publication number
AU2011234656B2
AU2011234656B2 AU2011234656A AU2011234656A AU2011234656B2 AU 2011234656 B2 AU2011234656 B2 AU 2011234656B2 AU 2011234656 A AU2011234656 A AU 2011234656A AU 2011234656 A AU2011234656 A AU 2011234656A AU 2011234656 B2 AU2011234656 B2 AU 2011234656B2
Authority
AU
Australia
Prior art keywords
peptide
construct
vaccine composition
disease
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011234656A
Other languages
English (en)
Other versions
AU2011234656A1 (en
Inventor
Katja Baer
Ana Graf
Marie-Jose Hoellinger
Georges Imbert
Marie-Emmanuelle Riviere
Peter Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011234656(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011234656A1 publication Critical patent/AU2011234656A1/en
Application granted granted Critical
Publication of AU2011234656B2 publication Critical patent/AU2011234656B2/en
Priority to AU2013221980A priority Critical patent/AU2013221980A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2011234656A 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant Ceased AU2011234656B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013221980A AU2013221980A1 (en) 2010-03-29 2013-08-29 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10158273.2 2010-03-29
EP10158273 2010-03-29
US36169710P 2010-07-06 2010-07-06
US61/361,697 2010-07-06
PCT/EP2011/054735 WO2011120924A1 (en) 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013221980A Division AU2013221980A1 (en) 2010-03-29 2013-08-29 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Publications (2)

Publication Number Publication Date
AU2011234656A1 AU2011234656A1 (en) 2012-10-11
AU2011234656B2 true AU2011234656B2 (en) 2013-08-01

Family

ID=42285305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011234656A Ceased AU2011234656B2 (en) 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Country Status (24)

Country Link
US (4) US20130011431A1 (enExample)
EP (1) EP2552489A1 (enExample)
JP (2) JP6088422B2 (enExample)
KR (1) KR20130018407A (enExample)
CN (2) CN102834118A (enExample)
AR (1) AR080810A1 (enExample)
AU (1) AU2011234656B2 (enExample)
BR (1) BR112012024708A2 (enExample)
CA (1) CA2793580A1 (enExample)
CL (1) CL2012002685A1 (enExample)
CO (1) CO6630127A2 (enExample)
EC (1) ECSP12012180A (enExample)
GT (1) GT201200265A (enExample)
IL (1) IL221540B (enExample)
MA (1) MA34084B1 (enExample)
MX (1) MX2012011340A (enExample)
NZ (1) NZ601729A (enExample)
PE (1) PE20130642A1 (enExample)
PH (1) PH12012501683A1 (enExample)
RU (1) RU2603486C2 (enExample)
SG (2) SG10201505374TA (enExample)
TN (1) TN2012000431A1 (enExample)
TW (2) TW201138805A (enExample)
WO (1) WO2011120924A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
DK3137094T3 (da) * 2014-04-29 2023-02-27 Advantage Therapeutics Inc Behandling og forebyggelse af alzheimers sygdom (ad)
KR102388363B1 (ko) * 2014-04-29 2022-04-19 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
WO2026155574A1 (ko) * 2025-01-15 2026-07-23 주식회사 포스백스 파필로마바이러스 바이러스 유사입자 기반 항-아밀로이드 베타 동물용 백신

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016282A1 (en) * 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
WO2006048295A1 (en) * 2004-11-05 2006-05-11 Novartis Ag Composition compri sing vlp and amyloid - beta peptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
CA2295740A1 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
NZ554387A (en) * 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016282A1 (en) * 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
WO2006048295A1 (en) * 2004-11-05 2006-05-11 Novartis Ag Composition compri sing vlp and amyloid - beta peptide

Also Published As

Publication number Publication date
US20150297692A1 (en) 2015-10-22
CO6630127A2 (es) 2013-03-01
RU2603486C2 (ru) 2016-11-27
SG10201505374TA (en) 2015-08-28
JP2013523682A (ja) 2013-06-17
PH12012501683A1 (en) 2012-11-05
EP2552489A1 (en) 2013-02-06
TW201618806A (zh) 2016-06-01
PE20130642A1 (es) 2013-06-19
US20130011431A1 (en) 2013-01-10
MX2012011340A (es) 2012-11-16
CA2793580A1 (en) 2011-10-06
CN104436212A (zh) 2015-03-25
JP6088422B2 (ja) 2017-03-01
TN2012000431A1 (en) 2014-01-30
JP2017008035A (ja) 2017-01-12
TW201138805A (en) 2011-11-16
CL2012002685A1 (es) 2013-01-25
BR112012024708A2 (pt) 2016-06-07
AR080810A1 (es) 2012-05-09
IL221540B (en) 2018-11-29
US20160101167A1 (en) 2016-04-14
SG183806A1 (en) 2012-10-30
MA34084B1 (fr) 2013-03-05
AU2011234656A1 (en) 2012-10-11
US20140348871A1 (en) 2014-11-27
KR20130018407A (ko) 2013-02-21
WO2011120924A1 (en) 2011-10-06
GT201200265A (es) 2014-03-14
CN102834118A (zh) 2012-12-19
ECSP12012180A (es) 2012-10-30
NZ601729A (en) 2013-10-25
RU2012145734A (ru) 2014-05-10

Similar Documents

Publication Publication Date Title
US20130011431A1 (en) Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant
JP2024178161A (ja) リン酸化タウペプチドワクチンの安全な投与の方法
US10857216B2 (en) Methods and kits for use in preventing and treating vulvovaginal candidiasis
KR20230087495A (ko) 알츠하이머 질환을 치료하기 위한 β-아밀로이드 백신
Chackerian Virus-like particle based vaccines for Alzheimer disease
US8617566B2 (en) Composition comprising VLP and amyloid beta peptide
AU2013221980A1 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
AU2011253800B2 (en) Composition comprising VLP and amyloid-beta peptide
HK1150961A (en) Composition comprising vlp and amyloid-beta peptide
JP2008515851A (ja) Ｖｌｐ−抗原コンジュゲートとワクチンとしてのその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired